Multicenter Cohort Study on Predicting Bronchiectasis Progression, Complications, and Prognosis Using Multi-omics

NCT ID: NCT07263373

Last Updated: 2025-12-04

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 2000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2020-01-01
• Study Completion Date: 2025-07-31

Brief Summary

Bronchiectasis is a heterogeneous condition with diverse etiologies and clinical manifestations. Its progression involves a vicious cycle of airway inflammation, recurrent infection, and structural damage, leading to persistent symptoms and declining lung function. Current management focuses on airway clearance and antibiotics, with no disease-modifying therapies available. Recognizing this heterogeneity is crucial for advancing targeted treatments and precision medicine.

Radiomics converts medical images into mineable data to reveal underlying pathophysiology. While applied in other respiratory diseases, its potential in bronchiectasis remains underexplored. Both radiomics and the lung microbiome are independently linked to disease severity in conditions like COPD, but their interplay is unclear. Integrating these modalities with clinical data could unlock novel insights, identify new therapeutic targets, and improve diagnostic and prognostic models.

However, few studies have investigated multimodal models combining radiomics, microbiome, and clinical features to predict outcomes in bronchiectasis. To address this gap, we designed a multicenter, retrospective study. It will analyze data from patients diagnosed between January 2020 and July 2025 to evaluate the combined value of radiomics, microbial features, and clinical parameters in diagnosing and predicting the progression of bronchiectasis.

Conditions

Bronchiectasis Adult; Radiomics

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: RETROSPECTIVE

Study Groups

Bronchiectasis

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• ① Diagnosis of bronchiectasis;

• Availability of both raw high-resolution computed tomography (HRCT) chest images and the corresponding radiology report; ③ Age ≥ 18 years.

Exclusion Criteria

• ① Incomplete clinical data;

• Absence of chest CT imaging studies and reports; ③ Other patients deemed ineligible for enrollment at the investigator's discretion.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The First Affiliated Hospital with Nanjing Medical University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

The First Affiliated Hospital of Nanjing Medical University，

Nanjing, Jiangsu, China

Countries

China

Other Identifiers

2025-SR-695

Identifier Type: -

Identifier Source: org_study_id